By using the macrocyclic oxamido−copper(II) complex as a building block and N 3 - and Cl - as auxiliary bridged groups, a binuclear complex and two tetranuclear complexes derived from the binuclear species have been prepared by stepwise synthesis and characterized. Their formulas are Cu( μ - exo O 2 )cyclam ( 1 ), [Cu( μ - exo O 2 )cyclamCu(tmen)](ClO 4 ) 2 ·H 2 O ( 2 ), {[Cu( μ - exo O 2 )cyclamCu( μ -1,3-N 3 ) 0.5 (tmen)] 2 (ClO 4 ) 4, [Cu( μ - exo O 2 )cyclamCu( μ -1,3-N 3 ) 0.5 (tmen)] 2 (ClO 4 ) 2 } ( 3 ), and [Cu( μ - exo O 2 )cyclamCu( μ -Cl) 0.5 (tmen)] 2 (ClO 4 ) 3 ( 4 ), where tmen = N,N,N ‘ N ‘ -tetramethylethylenediamine and ( exo O 2 )cyclam = 1,4,8,11-tetraazacyclotradecanne-2,3-dione. The structure of complex 1 consists of the neutral copper(II) complex of the [14]N 4 macrocyclic oxamido dianion, and the packing of the molecules along the b orientation results in a novel one-dimensional wavelike chain through weak coordination bonds and hydrogen bonds. The structure of complex 2 consists of binuclear cations, a weakly coordinated water molecule, and perchlorate anions, and the structures of 3 and 4 consist of tetranuclear cations derived from binuclear species through azide and chloride ligands, respectively, and perchlorate anions.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: